In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species

被引：46

作者：

Citron, Diane M. ^{[1
]}

Tyrrell, Kerin L. ^{[1
]}

Merriam, C. Vreni ^{[1
]}

Goldstein, Ellie J. C. ^{[1
,2
]}

机构：

[1] RM Alden Res Lab, Culver City, CA 90230 USA

[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2012年 / 56卷 / 03期

关键词：

RESISTANT ENTEROCOCCI; FIDAXOMICIN OPT-80; OVERGROWTH; MICROBIOTA; INFECTION;

D O I：

10.1128/AAC.05655-11

中图分类号：

Q93 [微生物学];

学科分类号：

071005 [微生物学];

摘要：

MICs of CB-183,315, a novel lipopeptide antibiotic, vancomycin, and metronidazole were determined for intestinal anaerobes and Enterobacteriaceae. The MIC(90)s for Gram-negative anaerobes were > 8,192, 8,192, and 4 mu g/ml for CB-183,315, vancomycin, and metronidazole, respectively. Against Enterobacteriaceae, the MIC(90)s were > 8,192 mu g/ml, 1,024 mu g/ml, and 1,024 mu g/ml, respectively. The CB-183,315 MIC90 for Clostridium difficile was 0.5 mu g/ml. Its lack of activity against normal fecal organisms makes it a promising new agent for treating C. difficile.

引用

收藏

页码：1613 / 1615

页数：3

相关论文

共 20 条

[1]

Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease [J].

Al-Nassir, Wafa N. ;

Sethi, Ajay K. ;

Li, Yuejin ;

Pultz, Michael J. ;

Riggs, Michelle M. ;

Donskey, Curtis J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2403-2406

[2]

Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients [J].

Bhalla, A ;

Pultz, NJ ;

Ray, AJ ;

Hoyen, CK ;

Eckstein, EC ;

Donskey, CJ .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2003, 24 (09) :644-649

[3]

DEVELOPMENT OF A RAPID AND EFFICIENT RESTRICTION-ENDONUCLEASE ANALYSIS TYPING SYSTEM FOR CLOSTRIDIUM-DIFFICILE AND CORRELATION WITH OTHER TYPING SYSTEMS [J].

CLABOTS, CR ;

JOHNSON, S ;

BETTIN, KM ;

MATHIE, PA ;

MULLIGAN, ME ;

SCHABERG, DR ;

PETERSON, LR ;

GERDING, DN .

JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (07) :1870-1875

[4]

Clinical and Laboratory Standards Institute, 2007, M11A7 CLIN LAB STAND, pM11

[5]

THE PHYLOGENY OF THE GENUS CLOSTRIDIUM - PROPOSAL OF 5 NEW GENERA AND 11 NEW SPECIES COMBINATIONS [J].

COLLINS, MD ;

LAWSON, PA ;

WILLEMS, A ;

CORDOBA, JJ ;

FERNANDEZGARAYZABAL, J ;

GARCIA, P ;

CAI, J ;

HIPPE, H ;

FARROW, JAE .

INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, 1994, 44 (04) :812-826

[6]

The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing [J].

Dethlefsen, Les ;

Huse, Sue ;

Sogin, Mitchell L. ;

Relman, David A. .

PLOS BIOLOGY, 2008, 6 (11) :2383-2400

[7]

Review of Current Literature on the Economic Burden of Clostridium difficile Infection [J].

Dubberke, Erik R. ;

Wertheimer, Albert I. .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2009, 30 (01) :57-66

[8]

Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy [J].

Edlund, C ;

Barkholt, L ;

OlssonLiljequist, B ;

Nord, CE .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (03) :729-732

[9]

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria [J].

Finegold, SA ;

Molitoris, D ;

Vaisanen, ML ;

Song, YL ;

Liu, CX ;

Bolaños, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4898-4902

[10]

Management of Clostridium difficile Infection: Thinking Inside and Outside the Box [J].

Gerding, Dale N. ;

Johnson, Stuart .

CLINICAL INFECTIOUS DISEASES, 2010, 51 (11) :1306-1313